Dermatologic Adverse Events from Cancer Treatments

The document from October 20, 2018, details the range of dermatologic adverse events (dAEs) that can occur as a result of cancer treatments, including effects on skin, hair, nails, and mucous membranes. These dAEs can significantly impact a patient's quality of life and may necessitate changes in cancer treatment regimens. Specific dAEs such as chemotherapy-induced alopecia (CIA), which affects 65% of patients, and skin reactions from EGFR inhibitors, affecting 75–90% of patients, are highlighted. The document also discusses the management of these dAEs, with strategies including preventive measures and both topical and systemic therapies. For severe cases, dose reduction or discontinuation of the cancer treatment may be necessary. The importance of early diagnosis and proper management of dAEs is emphasized to optimize anticancer response and maintain patient quality of life.